BRCA2 and breast carcinoma: An older study from 2022 with a larger sample composed of 42,680 female patients with diagnosed breast cancer from several countries associated TP53 mutations with HER2-positive breast cancer, but not with TNBC, while BRCA1 and BRCA2 variants were strongly present in this latter condition [132].